Issue Contents
|
Marketing Authorisations
|
|
|
Better than everolimus
|
|
|
|
|
|
Uncertain harm-benefit balance
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
Pravastatin is the first choice when statin therapy is justified
|
|
|
|
|
|
|
|
|
The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.
